Dr. Grunwald of the Atrium Health Levine Cancer Institute, discusses caring for patients with PV on rare disease day. Dr. Bob Walker discusses high blood pressure in the context of severe COVID-19 infection. Dr. Brooks explains the association between male sex and 5-FU exposure. Dr. Pakbaz describes some of the difficulties faced by patients with SCD as they switch from pediatric to adult programs. Marisa Bittoni, PhD, talks about a large-scale study exploring factors that lead to lung cancer in patients younger than 50. Cynthia Miller, MD, MPH, FACP, discusses why early Lp(a) screening may help prevent cardiovascular disease. Drs. Grant, Sutin, and Lin discuss their pilot study investigating cerebral hemodynamics in infants with sickle cell disease. What does the data and overall understanding of VEGF-TKIs tell us about which patients are optimal candidates for tivozanib? Dr. Pakbaz and Dr. Strouse discuss their experiences practicing classical hematology and where the speciality is heading. Dr. Pakbaz, from the University of California Irvine, shared data on the value of a dedicated classical hematology clinic. Incannex announces the first dosing in a phase 2 study of a novel drug combination comprising HCQ and CBD to treat RA. The FDA recently approved a new combination therapy for the treatment of HR-positive, HER2-negative breast cancer. Dr. Hobbs shared findings supporting the safety and feasibility of continuing ruxolitinib during and after HSCT for MF. Dr. Christopher Lieu gives an overview of some of the top presentations and data to look out for at ASCO GI 2024. Dr. Richard Lafayette discusses the FDA approval of TARPEYO, which reduces the loss of kidney function in IgA nephropathy. Dr. Lichaa describes the use of a transfusion filter to return filtered blood to a patient through a central access point. The panel shares their outlook for the future of MDS research and treatment. Dr. Tanaka outlines a biomarker study that observed reduced inflammation in patients with MDS treated with luspatercept. The panel discussed a study that assessed quality of life and PROs in patients receiving luspatercept for MDS. The panel discusses whether starting treatment with luspatercept sooner in patients with MDS is beneficial. Dr. Shammo shares her reaction to a study that assessed mutational burden and impact on primary outcomes in COMMANDS.